

Durham Research Online

Deposited in DRO:

06 June 2019

Version of attached file:

Accepted Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

Clososki, Giuliano Cesar and Steel, Patrick G. and Bertallo, Camila Rodrigues de Souza and Arroio, Thaís Rodrigues Arroio Rodrigues and Vessecchi, Ricardo and Toledo, Monica F. Z. J. and Sadler, Scott (2019) 'C-H activation/metalation approaches for the synthesis of indolizine derivatives.', *European journal of organic chemistry*, 31-32 . pp. 5205-5213.

Further information on publisher's website:

<https://doi.org/10.1002/ejoc.201900608>

Publisher's copyright statement:

This is the accepted version of the following article: Clososki, Giuliano Cesar, Steel, Patrick G., Bertallo, Camila Rodrigues de Souza, Arroio, Thaís Rodrigues Arroio Rodrigues, Vessecchi, Ricardo, Toledo, Monica F. Z. J. Sadler, Scott (2019). C-H activation/metalation approaches for the synthesis of indolizine derivatives. *European Journal of Organic Chemistry* 31-32: 5205-5213 which has been published in final form at <https://doi.org/10.1002/ejoc.201900608>. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

Additional information:

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.

Accepted Article

Title: C-H activation/metalation approaches for the synthesis of indolizine derivatives

Authors: Giuliano Cesar Clososki, Patrick G. Steel, Camila Rodrigues de Souza Bertallo, Thaís Rodrigues Arroio Rodrigues Arroio, Ricardo Vessecchi, Monica F. Z. J. Toledo, and Scott Sadler

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: *Eur. J. Org. Chem.* 10.1002/ejoc.201900608

Link to VoR: <http://dx.doi.org/10.1002/ejoc.201900608>

COMMUNICATION

C-H Activation / metalation approaches for the synthesis of indolizine derivatives

Camila R. de S. Bertallo,^[a] Thais R. Arroio,^[a] Mônica F. Z. J. Toledo,^[a] Scott D. Saddler,^[b] Ricardo Vessecchi,^[c] Patrick G. Steel,^[b] Giuliano C. Clososki^{*,[a,c]}

Abstract: The C-H borylation of indolizines has not previously been reported and in this communication, we describe our preliminary efforts to apply this chemistry to this scaffold and contrast this approach to directed metalation. Through these methodologies were possible obtain a library of substituted indolizines functionalized in both pyridinic and pyrrole ring.

Introduction

Indolizines represent a privileged class of heterocycles that have received considerable attention recently due to their significant and broad range of activities (Figure 1). This include roles in many biological active compounds such as anti-inflammatory,¹ anticancer,² antimicrobial,³ and antitubercular agents, among others.^{4–12} In addition, owing to the luminescent properties of this ring system, indolizine derivatives have found applications as bioprobes in pH and turn-on/off fluorescent sensors,^{13–15} in the detection of volatile organic compounds,¹⁶ lipid droplet accumulation,¹⁷ and in cell labeling.¹⁸ Moreover, substituted indolizines have found roles in organic sensitizer components for photoresponsive materials¹⁹ and dye-sensitized solar cells.²⁰




Figure 1. Some indolizines that present biological activity.

This diversity of function has encouraged the search for new and efficient methods to generate novel analogues. Aromatic indolizines are commonly prepared from pyridines and pyrroles by several synthetic strategies including the classic Tschitschabin reaction, cycloaddition reactions, intramolecular cyclizations, and cycloisomerisations.^{21–24} However, late stage modification of a preformed indolizine ring can be desirable and several strategies have been described. Given the electron rich nature of the heterocyclic ring electrophilic substitution is relatively facile leading to preferential substitution at C-1 and C-3.²⁵ Selective C-3 substitution can be achieved through palladium catalyzed C-H activation, although this probably also proceeds via a S_EAr mechanism. Direct lithiation of the ring is also possible. First reported by Renald and Gubin using 2-phenylindolizine as substrate,²⁶ this approach can be used to access a range of C-5 functionalized derivatives.²⁷ One limitation of this approach is functional group tolerance to the bases employed. In this regard we have been exploring the direct metalation of indolizines as well as other N-heterocycles²⁸ using lithium and the mixed lithium-magnesium bases $TMPMgCl \cdot LiCl$ and $TMP_2Mg \cdot 2LiCl$ ($TMP = 2,2,6,6$ -tetramethylpiperidiny).²⁹ Using indolizine-1-carboxylates as a model substrates the selective synthesis of a variety of C-2 and C-5 difunctionalized indolizines could be achieved.^{28e} An alternative functional group tolerant approach to C-H activation that is gaining significant popularity is C-H borylation mediated by Iridium tris-boryl complexes.³⁰ The C-H borylation of indolizines has not previously been reported and in this communication, we describe our preliminary efforts to apply this chemistry to this scaffold and contrast this approach to directed metalation.

[a] Camila R. de S. Bertallo, Thais R. Arroio, Dr. Mônica F. Z. J. Toledo and Prof. Dr. Giuliano C. Clososki
Núcleo de Pesquisas em Produtos Naturais e Sintéticos, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Av. do Café S/N, Ribeirão Preto - SP 14040-903, Brazil
Corresponding Author: Prof. Dr. Giuliano C. Clososki
E-mail: gclososki@fcfrp.usp.br,
<http://fcfrp.usp.br/pg/pct/corpo-docente/giuliano-cesar-clososki/>
ORCID: 0000-0001-7605-4150

[b] Prof. Dr. P. G. Steel and Dr. Scott D. Saddler
Department of Chemistry, Durham University
South Road, Durham DH1 3LE (UK).
E-mail: p.g.steel@durham.ac.uk
ORCID: 0000-0002-2493-5826


[c] Prof. Dr. Ricardo Vessecchi
Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto - SP 14040-901, Brazil
Supporting information for this article is given via a link at the end of the document.

COMMUNICATION

Results and Discussion

With the aim of comparing the two C-H activation procedures we selected a small focused set of indolizines containing functional groups that have previously been shown to enable directed metalation chemistry. The nitriles (**5**, **6**) and diester **9** could easily be prepared through cycloaddition of pyridine derived ylid and the acrylonitrile and dimethyl fumarate respectively.³¹


With substrates in hand we then considered their borylation using as a standard reagent, the catalyst derived from $[\text{Ir}(\text{OMe})\text{cod}]_2/\text{dtbpy}$ (4,4'-di-*t*-butylbipyridine) and B_2Pin_2 as the source of boron.^{32,33} As the Ir catalyzed borylation of the parent indolizine has not been previously reported we initially explored this substrate to ascertain if there was any intrinsic selectivity within this heterocyclic scaffold. Surprisingly, given the latent azole within the indolizine structure this proved to be a rather reluctant substrate requiring elevated temperatures (80°C) to observe any significant reactivity. Moreover, in line with many unsubstituted polycyclic arenes, at this temperature, the unhindered nature of the substrate led to a complex mixture of both mono- and bis-borylated products. Introduction of an additional heteroatom into the five membered ring (compounds **1** and **3**) enhanced the reactivity with borylation occurring remote from the azinyl nitrogen as would be expected.³⁴ In both cases the initially formed boronate ester proved difficult to purify and confirmation of regiochemistry was obtained by in situ Suzuki-Miyaura cross coupling reactions that afforded products **2** and **4** in 31 and 41% yields, respectively (Scheme 1).



Scheme 1. C-H borylations of **1** and **3** followed by Suzuki-Miyaura cross coupling reactions.

The addition of an electron withdrawing substituent is also well known to be strongly activating towards borylation. In particular, benzonitriles are viable substrates in which the substituent has only a limited steric influence. In line with this precedent, 2-cyanoindolizine **5** reacted to afford a complex mixture of mono-borylated and di-borylated products (Scheme 2, equation a). Within this, substitution at C-1 and C-3 in the five membered ring was favored consistent both with the known propensity for a nitrile to activate *ortho* C-H bonds to borylation and the high reactivity of azole rings. Whilst at higher temperatures and longer reactions time 1-cyanoindolizine **6** gave a similar output, lowering both the reaction temperature and time led to the formation of only two regioisomers at C-3 (compound **7a**) or C-6 (compound **8a**), albeit with only low conversion (45% by GC/MS).

As isolation of the boronate esters was challenging it proved more practical to undertake a one pot conversion to the corresponding biaryls (**7a**, **7b**, **8a** and **8b**) which could be achieved in moderate overall yields (Scheme 2, equations b and c). Subsequently, we then turned to explore the diester **9**. Pleasingly, this combination of greater steric influence coupled with a strong electron withdrawing effect proved to be successful. After some experimentation, the best combination of selectivity and conversion (87% by GC/MS) was achieved using MTBE as solvent with 5 mol% of $[\text{Ir}(\text{OMe})\text{cod}]_2$, 10 mol% dtbpy and 1.0 equivalent of B_2Pin_2 at 80°C for 4h. This led to a mixture of borylated products that proved difficult to resolve so a one pot tandem C-H borylation Suzuki-Miyaura cross coupling process was established. In this, following completion of the borylation step, the reaction mixture was concentrated in vacuo and $\text{Pd}(\text{dppf})\text{Cl}_2$, K_3PO_4 and dimethylacetamide (DMAc)/ H_2O (2:1) added.³⁵ As shown in equation d (Scheme 2), this led to the formation of two arylated indolizine regioisomers (compounds **10** and **11**) and a di-arylated product **12** with the major product being the C-5 arylated product **10** (48% isolated yield). The formation of the C-5,6 diarylated derivative **12** was particularly intriguing as the possibility of formation of an intermediate with *ortho* Bpin groups is normally sterically inhibited.



Scheme 2. C-H borylation of **5**, **6** and **9** followed by Suzuki-Miyaura cross coupling reactions.

Having demonstrated that the borylation of indolizines was possible we then turned to examine the substituted indolizines (**5**, **6** and **9**) in the direct metalation process. In all cases we used the trapping reaction with iodine as a standard marker of selectivity. We had previously employed the directed regioselective metalation of 1-ester-substituted indolizines using LDA and $\text{TMPMgCl} \cdot \text{LiCl}$ under mild conditions. Application of this strategy allowed the synthesis of a variety of C-2 and C-5 difunctionalized indolizines after reaction of the corresponding organometallic

COMMUNICATION

intermediates with different electrophiles.^{28e} In a similar fashion, we evaluated the reactivity of diester **9** using lithium and magnesium amides. Interesting, albeit no reaction was observed using LDA or TMPLi, the metalation occurred smoothly at room temperature within 5h using 2 equivalents of TMPMgCl·LiCl, as verified by CG-MS analysis of the crude reaction mixtures quenched with iodine. On a preparative scale, solvent extraction and purification with flash chromatography allowed iodide **13a** to be isolated in 87% yield (Table 1, entry 1). Moreover, quenching intermediate with dimethylformamide gave the trisubstituted indolizine bearing an aldehyde group at C-5 position **13b** with 60% yield (Table 1, entry 2). Remarkably, as already observed in other indolizine substrates,²⁹ a regioselectivity dependent upon the electrophile was observed when the reaction was quenched with diphenyldisulfide to give **14a** (Table 1, entry 3). The same regioselectivity was observed in palladium-catalyzed coupling reactions, important tools to functionalize aromatics and heterocyclic substrates.³⁶ After, transmetalation of the organomagnesium intermediate with ZnCl₂, Negishi cross-coupling reactions with iodobenzene or 1-bromo-4-(trifluoromethyl)benzene in the presence of [Pd(PPh₃)₄] (10mol%) produced the C-3 arylated derivatives **14b** or **14c** in 64 and 76% yields, respectively (Table 1, entries 4 and 5).





Table 1. Selective metalation of **5** followed by reaction with electrophiles.

Entry	Electrophile	Product	Yield (%) ^[a]
1	I ₂		87
2	DMF		60
3	(C ₆ H ₅ S) ₂		75
4	PhI		64 ^[b]
5	Br(C ₆ H ₄)CF ₃		76 ^[b]

^[a]Isolated yields, ^[b]Obtained via Negishi cross-coupling using 10 mol% Pd(PPh₃)₄ after transmetalation with 2 equiv. of ZnCl₂ at rt for 30 min.

This divergence in selectivity potentially arises through a dynamic equilibrium between the anionic species since pKa calculations (computed at B3LYP/6-31+G(d,p) level in Gaussian 03 software)³⁷ indicate similar acidity of the hydrogens at C-3 and C-5 positions (Scheme 3). We speculate that the generation of the C-3 anion is favored by chelation of the magnesium counter-ion by the proximal ester. Consistent with this hypothesis, *in situ* trapping³⁸ experiments with chlorotrimethylsilane afforded the corresponding 3-silylated derivative as the major product (see SI). Disruption of the chelate by a coordinating electrophile (iodide) allows anion equilibration and leads to formation of the sterically less hindered anion and formation of the 5-substituted product. In contrast reaction with non-coordinating reagents (ZnCl₂) traps the coordinated anion faster than exchange can occur. Whilst a base mediated halogen dance³⁹ provides an alternative mechanism that leads to the formation of iodide **13a**, that cannot be excluded, the order of events with addition of the electrophile (I₂) only occurring after complete metalation leads us to favor the former scenario.




Scheme 3. Dynamic equilibrium of anionic species derived from the reaction of **9** with TMPMgCl·LiCl

With 1-cyanoindolizine **6**, complete metalation was achieved within 30 min using 1.4 equivalents of LDA at 0°C leading, on reaction with iodine, and isobutyraldehyde to the C-5 indolizine derivatives **15a-b**, respectively (Scheme 4, equations a and b). This result is consistent with simple pKa calculations (See SI) which reveal that the C-5 hydrogen is the more acidic (pKa 26.0). On switching to the magnesium bases, an *ortho* metalation effect enabled by the cyano group was expected leading to the formation of the C-2 substituted products. However, a dependence on the electrophile was again observed with the isobutyraldehyde reacting at C-2 to give **16a** (Scheme 4, equation c) possibly via a chelate mechanism, whilst the iodide, as previously noted, disrupted the weak chelation to the nitrile group leading to rapid anion isomerization and formation of the C-5 product **15a** (Scheme 4, equation d). The metalation of 2-cyanoindolizine **5** was best achieved using the mixed lithium magnesium bases TMPMgCl·LiCl and TMP₂Mg·2LiCl. As before, the ultimate product isolated depended on the nature of the electrophile. Thus, reaction of **5** with 3 equivalents of TMPMgCl·LiCl for 1 hour followed by addition of trimethylsilyl chloride gave the C-3 silylated derivative **17b** in 67% yield (Scheme 4, equation e). Functionalization at C-3 position was also observed when the same reaction was quenched with hexachloroethane, allowing the isolation of chloride **17b** in 62% yield (Scheme 4, equation f). A very similar result was obtained when the diamide TMP₂Mg·2LiCl was used as a base (2 equiv),

COMMUNICATION

leading to the same product **17b** in 63% yield (Scheme 4, equation g). In contrast, quenching the reaction with iodine afforded the C-5 substituted product **18a** in 47% yield (Scheme 4, equation h).



Scheme 4. Selective metalation of cyanoindolizines **5** and **6**

Conclusions

In this report, we have described for the first time the C-H borylation of indolizines, which allowed the synthesis of arylated derivatives after *in situ* Suzuki-Miyaura cross coupling reactions. Directed metalation of the same substrates followed by reaction with electrophiles afforded the functionalized derivatives in reasonable to good yields, with the

regioselectivity of the reactions being dependent upon the base and electrophile used. DFT calculations illustrated how the substituents affect the acidity of the aromatic hydrogens. In summary, these two strategies enable the selective access to a set of substituted indolizines functionalized in either pyridinic or pyrrole ring. The scope of these methodologies and their applicability towards the synthesis of biologically active molecules are currently being investigated in our laboratories.

Experimental Section

The solvents were purified according to standard procedures. The starting materials were purchased from Sigma-Aldrich Corp. All air-sensitive and/or water-sensitive reactions were carried out with dry solvents under anhydrous conditions and under nitrogen atmosphere. Standard syringe techniques were applied for the transfer of dry solvents and air-sensitive reagents. The reactions were monitored by TLC on Merck silica gel (60 F 254) by using UV light as a visualizing agent and 5% vanillin in 10% H₂SO₄ with heating as a developing agent. Sigma-Aldrich silica gel (particle size 0.040–0.063 nm), pre-packed silica Redisep® Rf cartridges and pre-packed C18 silica Redisep® Rf cartridges (Teledyne Isco CombiFlash Rf machine) were used for flash chromatography. NMR spectra were recorded with a Bruker DPX 300, 400, 500 and 600 (at 300, 400, 500 and 600 MHz for ¹H and 75, 100, 125 and 151 MHz for ¹³C, respectively.) instrument while using CDCl₃ or DMSO-d₆ as solvent. The chemical shifts are reported as δ units in parts per million (ppm) relative to the solvent residual peak as the internal reference. Infrared (IR) spectra of all synthesized compounds were recorded on Perkin-Elmer mod.1420 in KBr pellets or in a Diamond ATR (attenuated total reflection) accessory (Golden Gate). Assigned peaks are reported in wavenumbers (cm⁻¹). Mass spectra (MS) were measured with Shimadzu GCMS-QP2010 mass spectrometer. HRMS spectra were measured with a Bruker Daltonics micrOTOF QII/ESI-TOF, LTQFT mass spectrometer or QToF mass spectrometer. Dimethyl indolizine-1,2-dicarboxylate, indolizine-1-carbonitrile, indolizine-2-carbonitrile and [Ir(OMe)cod]₂ were prepared as previously reported.³⁰

General Procedure 1A: In a glovebox, a premixed solution of [Ir(COD)OMe]₂ (1.5 mol%), dtbpy (3 mol%) and B₂pin₂ (0.5 equiv) (or HBpin (1.0 equiv) where stated) in MTBE (2.5 mL) was added to a thick-walled microwave synthesis vial containing the stated heterocycle (1.0 equiv). The mixture was shaken vigorously to ensure complete mixing, and then the mixture was stirred at room temperature or heated at 80 °C for the stated time. In-situ NMR reaction monitoring was carried out. The reaction was stirred for 16 h at room temperature before being concentrated in vacuo. A tandem Suzuki-Miyaura cross-coupling reaction was then carried out. To the crude borylation mixture under N₂, was added Pd(Amphos)Cl₂ (40 mg, 0.056 mmol), Na₂CO₃(aq) (2M, 197 mg, 1.86 mmol), 3-iodo-fluorobenzene (248 mg, 1.12 mmol) in DME (3 mL) at 80 °C for 3 h. The reaction mixture was diluted with water and extracted into EtOAc. The organic phase was dried over MgSO₄, filtered and concentrated in vacuo to give the crude product.

3-(3-fluorophenyl)pyrazolo[1,5-a]pyridine 2: From 3-(3-fluorophenyl)pyrazolo[1,5-a]pyridine (110 mg, 0.93 mmol) and 3-iodofluorobenzene (248 mg, 1.12 mmol). Purification by reverse phase chromatography using pre-packed C18 silica Redisep® Rf cartridges and a 0–100% MeOH in H₂O (containing 0.1% HCOOH) gradient elution, constant of flow 35 mL/min. Yield: 61 mg, (31%), pale yellow oil. ¹H NMR (600 MHz, CDCl₃, 25 °C) δ 8.38 (d, *J* = 7.7, 1H), 8.03 (s, 1H), 7.69 (d, *J* = 7.7, 1H), 7.35 (m, 2H), 7.24 (m, 1H), 7.16 (t, *J* = 7.7, 1H), 6.95 (m, 1H), 6.77 (t, *J* = 7.7, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 163.4 (d, *J*_{FC} = 246.0 Hz), 140.6, 137.1, 135.5, 130.6, 129.3, 124.5, 122.7, 117.4, 113.7 (d, *J* = 22.0), 113.0 (d, *J*_{FC} = 21.1 Hz), 112.3, 111.9 (d, *J*_{FC} = 2.3 Hz). IR ν_{max} (ATR) 1634, 1613, 1584, 1546, 1531, 1453, 1366, 1260, 1217, 1178,

COMMUNICATION

1017, 904 cm^{-1} . HRMS (ESI) m/z ($[M+H]^+$) calcd for $\text{C}_{13}\text{H}_{10}\text{N}_2\text{F}$ 213.0828, found 213.0814.

General Procedure 1B : In a glovebox, a premixed solution of $[\text{Ir}(\text{COD})\text{OMe}]_2$ (1.5 mol%), dtbpy (3 mol%) and B_2pin_2 (1.0 equiv) (or HBpin (1.0 equiv) where stated) in MTBE (2.5 mL) was added to a thick-walled microwave synthesis vial containing pyrazolo[1,2-*a*]pyridine **3** (118 mg, 1 mmol). The mixture was shaken vigorously to ensure complete mixing, and then the mixture was stirred at 80 °C for 24 h. In-situ NMR reaction monitoring was carried out. The 3-(Bpin) desired product was obtained in 85% conversion (^1H NMR). The Suzuki-Miyaura step was carried out for 2 h with $\text{Pd}(\text{Amphos})\text{Cl}_2$ (39 mg, 0.05 mmol), K_3PO_4 (425 mg, 2 mmol), 3-iodoanisole (257 mg, 1.1 mmol) in DMAc:H₂O (10:1) (2.5 mL) at 50 °C. The reaction mixture was diluted with water and extracted into EtOAc. The organic phase was dried over MgSO_4 , filtered and concentrated in vacuo to give the crude product.

3-(3-methoxyphenyl)imidazo[1,2-*a*]pyridine 4: From pyrazolo[1,2-*a*]pyridine **3** (118 mg, 1 mmol) and 3-iodoanisole (257 mg, 1.1 mmol). Purification was achieved using automated Teledyne Isco CombiFlash Rf machine with a pre-packed silica Redisep® Rf cartridges (ethyl acetate/hexane 0-50%) at a constant flow rate of 35 mL/min. Yield: 92 mg (41%), grey amorphous solid. ^1H NMR (700 MHz, CDCl_3 , 25 °C) δ 8.37 (d, J = 7.6, 1H), 7.70 (s, 1H), 7.67 (d, J = 7.6, 1H), 7.43 (t, J = 7.9, 1H), 7.20 (m, 1H), 7.15 (d, J = 7.9, 1H), 7.09 (m, 1H), 6.96 (dd, J = 7.9, 1.9, 4.1H), 6.81 (t, J = 7.6, 1H), 3.87 (s, 3H); ^{13}C NMR (176 MHz, CDCl_3) δ 160.2, 146.2, 132.6, 130.6, 130.2, 125.6, 124.2, 123.5, 120.2, 118.3, 113.7, 113.5, 112.5, 55.4. IR ν_{max} (ATR) 1602, 1580, 1501, 1299, 1283, 1237, 1165, 1047 cm^{-1} ; HRMS (ESI) m/z ($[M+H]^+$) calcd for $\text{C}_{14}\text{H}_{13}\text{N}_2\text{O}$ 225.1030, found 225.1019.

General Procedure 1C: One-pot C-H borylation/Suzuki-Miyaura Cross-coupling of substituted indolizines

A thick-walled microwave synthesis vial was charged with the corresponding indolizine (0.5 mmol, 1.0 equiv) and degassed MTBE (1 mL) (vial A). A separate vial was charged with $[\text{Ir}(\text{COD})\text{OMe}]_2$ (5 mol%), dtbpy (10 mol%), B_2pin_2 (1.0 equiv) and it was evacuated and placed under N_2 with three evacuation/refill cycles, before degassed MTBE was added. The vial was sealed with a crimp top septum cap and shaken to develop a deep red colour. Once it was homogeneous, the solution of vial A was added to vial B. The vial was heated (vide Scheme 2) for 1 h or 4 h. Upon completion (determined by GC-MS) the volatiles were removed in vacuo to afford the crude boronate product. $\text{Pd}(\text{dppf})\text{Cl}_2$ (10 mol%), K_2PO_3 (1 equiv.) and aryl halide (Scheme 2; 1.3 equiv) were added, and the vial was sealed and purged with three evacuation/refill (Ar) cycles. DMAc:H₂O (2 mL/1 mL) was added, and the mixture was heated to 80 °C for 12 h in an oil bath. The reaction mixture was diluted with water (10 mL) and extracted with AcOEt (3 \times 10 mL). The combined organic extracts were washed with brine (10 mL), dried over anhydrous MgSO_4 , filtered through Celite, and concentrated in vacuo to afford the crude product. The residue was purified by pre-packed silica Redisep® Rf cartridges with the stated solvent gradient and at a constant flow rate of 35 mL/min using an automated Teledyne Isco CombiFlash Rf machine.

3-phenylindolizine-1-carbonitrile 7a: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and iodobenzene (0.07 mL, 0.65 mmol), pre-packed silica Redisep® Rf cartridges (ethyl acetate/hexane 2/8), yield: 33 mg (30%), brown oil. ^1H NMR (600 MHz, CDCl_3 , 25 °C) δ 8.28 (d, J = 7.2 Hz, 1H), 7.70 (d, J = 9.0 Hz, 1H), 7.55 – 7.50 (m, 4H), 7.46 – 7.42 (m, 1H), 7.09 (ddd, J = 9.0, 6.6, 1.0 Hz, 1H), 7.05 (s, 1H), 6.74 (td, J = 6.8, 1.3 Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 138.6, 130.4, 129.4, 128.9, 128.8, 127.1, 126.7, 123.9, 122.5, 118.4, 117.1, 116.4, 113.2, 82.4. Accurate mass (EI): calcd for $\text{C}_{15}\text{H}_{10}\text{N}_2$ 218.0844, found 218.0927.

6-phenylindolizine-1-carbonitrile 8a: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and iodobenzene (0.07 mL, 0.65 mmol), pre-packed silica Redisep® Rf cartridges (ethyl acetate/hexane 1/9), yield: 11 mg (10%), brown oil. ^1H NMR (600 MHz, CDCl_3 , 25 °C) δ 8.20 (t, J = 1.3 Hz, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.58 – 7.54 (m, 2H), 7.48 (dd, J = 8.4, 7.0 Hz, 2H), 7.44 – 7.39 (m, 1H), 7.34 (dd, J = 9.3, 1.6 Hz, 1H), 7.31 (d, J = 3.0 Hz, 1H), 7.06 (d, J = 2.9 Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 129.3, 128.3, 127.6, 127.0, 123.4, 120.4, 118.0, 117.6, 117.0, 114.5. Accurate mass (EI): calcd for $\text{C}_{15}\text{H}_{10}\text{N}_2$ 218.0844, found 218.0952.

3-(4-(trifluoromethyl)phenyl)indolizine-1-carbonitrile 7b: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and 1-bromo-4-(trifluoromethyl)benzene (0.09 mL, 0.65 mmol), pre-packed silica Redisep® Rf cartridges (ethyl acetate/hexane 2/8), yield: 42 mg (33%), pale yellow solid, mp: 157–158 °C. ^1H NMR (700 MHz, CDCl_3 , 25 °C) δ 8.29 (dt, J = 7.1, 1.1 Hz, 1H, H-5), 7.80 – 7.76 (m, 2H), 7.72 (dt, J = 9.0, 1.2 Hz, 1H, H-2'), 7.68 – 7.64 (m, 2H), 7.14 (ddd, J = 9.0, 6.6, 1.0 Hz, 1H, H-7), 7.12 (s, 1H, H-3), 6.81 (td, J = 6.9, 1.3 Hz, 1H, H-6). ^{13}C NMR (176 MHz, CDCl_3) δ 139.0, 133.9, 130.5 (q, J_{FC} = 32.7 Hz, C-4') 128.80, 126.4 (q, J_{FC} = 3.7 Hz, 2C, C-3', C-5'), 125.5, 124.8 (q, J_{FC} = 272 Hz, CF₃), 123.6, 123.2, 123.1, 118.6, 117.3, 116.5, 113.8, 83.1. Accurate mass (EI): calcd for $\text{C}_{16}\text{H}_9\text{F}_3\text{N}_2$ 286.0718, found 286.0820.

6-(4-(trifluoromethyl)phenyl)indolizine-1-carbonitrile 8b: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and 1-bromo-4-(trifluoromethyl)benzene (0.09 mL, 0.65 mmol), pre-packed silica Redisep® Rf cartridges (ethyl acetate/hexane 2/8), yield: 17 mg (12%), brown oil. ^1H NMR (600 MHz, CDCl_3 , 25 °C) δ 8.11 (dd, J = 7.1, 0.9 Hz, 1H, H-5), 7.87 (dd, J = 1.8, 0.9 Hz, 1H, H-8), 7.77 – 7.72 (m, 4H), 7.30 (d, J = 3.1 Hz, 1H, H-3), 7.08 (d, J = 2.9 Hz, 1H, H-2), 7.04 (dd, J = 7.2, 1.9 Hz, 1H, H-7). ^{13}C NMR (151 MHz, CDCl_3) δ 141.7, 137.9, 133.8, 130.5 (q, J_{FC} = 32.6 Hz, C-4'), 127.08, 126.86, 126.1 (q, J_{FC} = 3.7 Hz, C-3', C-5'), 124.17 (q, J_{FC} = 272 Hz, CF₃), 117.98, 116.81, 115.56, 114.19, 112.58, 83.31. Accurate mass (EI): calcd for $\text{C}_{16}\text{H}_9\text{F}_3\text{N}_2$ 286.0718, found 286.0805.

Dimethyl-5-(4-(trifluoromethyl)phenyl)indolizine-1,2-dicarboxylate 10: From dimethyl indolizine-1,2-dicarboxylate (116.5 mg, 0.5 mmol) and 1-bromo-4-(trifluoromethyl)benzene (0.09 mL, 0.65 mmol), pre-packed silica Redisep® Rf cartridges (ethyl acetate/hexane 1/9), yield: 90 mg (48%), pale yellow solid, mp: 147 °C. ^1H NMR (600 MHz, CDCl_3 , 25 °C) δ 8.21 (ddd, J = 9.2, 1.2, 0.6 Hz, 1H, H-8), 7.83 (dt, J = 8.1, 0.8 Hz, 2H, H-3', H-5'), 7.73 – 7.70 (m, 2H, H-2', H-6'), 7.57 (d, J = 0.7 Hz, 1H, H-3), 7.17 (dd, J = 9.3, 6.8 Hz, 1H, H-7), 6.72 (dd, J = 6.8, 1.2 Hz, 1H, H-6), 3.93 (s, 3H), 3.87 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 165.2, 164.4, 137.3, 137.1, 136.6, 132.5, 132.3, 132.0 (q, J_{FC} = 32.8 Hz, C-4') 130.4, 129.4, 126.4 (q, J_{FC} = 3.7 Hz, C-3', C-5'), 126.6 (J_{FC} = 272 Hz, CF₃), 123.33, 122.91, 121.90, 120.32, 115.17, 114.86, 114.12, 103.75, 52.34, 51.57. Accurate mass (EI): calcd for $\text{C}_{19}\text{H}_{14}\text{F}_3\text{NO}_4$ 377.0875, found 377.0965.

Dimethyl-6-(4-(trifluoromethyl)phenyl)indolizine-1,2-dicarboxylate 11: From dimethyl indolizine-1,2-dicarboxylate (116.5 mg, 0.5 mmol) and 1-bromo-4-(trifluoromethyl)benzene (0.09 mL, 0.65 mmol), pre-packed silica Redisep® Rf cartridges (ethyl acetate/hexane 1/9), yield: 33 mg (12%), pale yellow solid, mp: 172–173 °C. ^1H NMR (600 MHz, CDCl_3 , 25 °C) δ 8.23 (dt, J = 9.5, 0.8 Hz, 1H, H-8), 8.16 (dd, J = 1.6, 1.0 Hz, 1H, H-5), 7.77 – 7.72 (m, 2H, H-3', H-5'), 7.72 (s, 1H, H-3), 7.67 (dt, J = 8.0, 0.8 Hz, 2H, H-2', H-6'), 7.33 (dd, J = 9.5, 1.6 Hz, 1H, H-7), 3.93 (d, J = 1.0 Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 164.8, 164.1, 140.4, 135.2, 130.3 (q, J_{FC} = 32.6 Hz, C-4'), 127.1, 126.6, 126.1 (q, J_{FC} = 3.9 Hz, C-3', C-5'), 126.11, 126.1, 124.0 (q, J_{FC} = 272 Hz, CF₃), 123.5, 123.3, 123.1, 122.3, 121.0, 117.5, 103.3, 52.2, 51.4. Accurate mass (EI): calcd for $\text{C}_{19}\text{H}_{14}\text{F}_3\text{NO}_4$ 377.0875, found 377.0965.

Dimethyl-5,6-bis(4-(trifluoromethyl)phenyl)indolizine-1,2-dicarboxylate 12: From dimethyl indolizine-1,2-dicarboxylate (116.5

COMMUNICATION

mg, 0.5 mmol) and 1-bromo-4-(trifluoromethyl)benzene (0.09 mL, 0.65 mmol), pre-packed silica Redisep® Rf cartridges (ethyl acetate/hexane 1/9), yield: 31 mg (12%), yellow solid, mp: 203–204°C. ¹H NMR (600 MHz, CDCl₃, 25°C) δ 8.50 (d, *J* = 1.6 Hz, 1H, H-8), 7.90 – 7.85 (m, 2H), 7.83 – 7.77 (m, 4H), 7.73 (d, *J* = 8.3 Hz, 2H), 7.59 (d, *J* = 0.6 Hz, 1H, H-3), 7.02 (d, *J* = 1.9 Hz, 1H, H-7), 3.95 (s, 3H), 3.89 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) 165.4, 164.8, 142.2, 137.5, 137.4, 135.2, 132.4, 132.2, 130.5, 130.3, 130.2, 129.3, 127.6, 127.0, 126.5 (q, *J*_{FC} = 3.6 Hz, 2C), 126.0 (q, *J*_{FC} = 3.7 Hz, 2C), 125.4, 124.0 (q, *J*_{FC} = 272 Hz, CF₃), 123.5 (q, *J*_{FC} = 298 Hz, CF₃), 118.1, 115.7, 114.7, 105.2, 52.8, 52.1. Accurate mass (EI): calcd for C₂₆H₁₇F₆NO₄ 521.1062, found 521.1141.

General Procedure 2 - Preparation of TMPMgCl·LiCl in THF: In a dry and nitrogen-flushed Schlenk flask equipped with a magnetic stirring bar and was charged with *i*-PrMgCl·LiCl (1.0 M in THF, 20 mL, 20 mmol). Then, 2,2,6,6-tetramethylpiperidine (3.52 mL, 21 mmol) was added dropwise through a syringe within 3 min. The mixture was stirred until the gas evolution ceased (24–48h). Titration against benzoic acid in THF (0°C) in the presence of 4-(phenylazo)diphenylamine as the indicator showed the base concentration ranged from 0.90 to 0.98 M.

General Procedure 3: Selective Magnesiation of indolizines: In a dry round-bottom flask sob N₂ under magnetic stirring containing 2 mL of THF and start material (0.50 mmol), amounts of TMPMgCl·LiCl (vide Table 1 and Scheme 3) was added dropwise to the reaction mixture. After stirring for 1h to 5h (see Table 1 and Scheme 3) a solution of an appropriate electrophile (1.8 equiv) in THF (1.0 mL) was added, and the reaction mixture was kept under stirring for 6h (for iodine) to 12h (other electrophiles). The reaction was quenched with saturated aqueous NH₄Cl, the products were extracted with ethyl acetate (3 × 15 mL), and the organic layer was dried over MgSO₄. The solvent was removed under reduction pressure. The residue was purified by flash column chromatography (silica gel, ethyl acetate/hexanes).

Dimethyl-5-iodoindolizine-1,2-dicarboxylate 13a: From dimethyl indolizine-1,2-dicarboxylate (116.5 mg, 0.5 mmol) and I₂ (342.64 mg, 0.9 mmol), silica gel (ethyl acetate/hexane: 2/8), yield: 156 mg (87%), brown solid, mp: 91–93°C. ¹H NMR (400 MHz, DMSO-*d*₆, 25°C) δ 8.04 (d, *J* = 9.1 Hz, 1H, H-8), 7.97 (s, 1H, H-3), 7.53 (dd, *J* = 7.1, 1.1 Hz, 1H, H-6), 6.98 (dd, *J* = 9.1, 7.0 Hz, 1H, H-7), 3.83 (s, 3H), 3.80 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 164.3, 163.4, 135.6, 125.9, 124.4, 121.0, 120.7, 118.8, 103.6, 91.5, 52.1, 51.3. HRMS (ESI) *m/z* ([M+H]⁺ calcd for C₁₂H₁₀NO₄ 359.9655, found 359.9729.

Dimethyl-5-formylindolizine-1,2-dicarboxylate 13b: From dimethyl indolizine-1,2-dicarboxylate (116.5 mg, 0.5 mmol) and DMF (0.12 mL, 1.5 mmol), silica gel (ethyl acetate/hexane: 3/7), yield: 78 mg (60%), brown oil. ¹H NMR (500 MHz, DMSO-*d*₆, 25°C) δ 9.95 (d, *J* = 10.5 Hz, 1H), 8.99 (s, 1H, H-3), 8.31 (d, *J* = 9.0 Hz, 1H, H-8), 7.95 – 7.85 (m, 1H, H-6), 7.43 (dd, *J* = 9.0, 7.0 Hz, 1H, H-7), 3.84 (d, *J* = 4.2 Hz, 6H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 187.0, 163.9, 163.1, 135.0, 131.0, 128.6, 125.7, 122.4, 122.1, 117.8, 104.5, 52.0, 51.5. HRMS (ESI) *m/z* ([M+H]⁺ calcd for C₁₃H₁₁NO₅ 262.0637, found 262.0713.

Dimethyl-3-(phenylthio)indolizine-1,2-dicarboxylate 14a: From dimethyl indolizine-1,2-dicarboxylate (116.5 mg, 0.5 mmol) and diphenylsulfane (131.0 mg, 0.6 mmol), silica gel (ethyl acetate/hexane: 3/7), yield: 128 mg (75%), orange oil. ¹H NMR (400 MHz, DMSO-*d*₆, 25°C) δ 8.44 (dd, *J* = 7.0, 1.2 Hz, 1H, H-8), 8.16 (dt, *J* = 9.0, 1.3 Hz, 1H, H-5), 7.43 (ddd, *J* = 9.1, 6.9, 1.1 Hz, 1H, H-6), 7.31 – 7.24 (m, 2H), 7.24 – 7.17 (m, 1H, H-7), 7.14 – 7.06 (m, 3H), 3.86 (s, 3H), 3.82 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 165.6, 163.0, 136.8, 133.7, 131.6, 129.9, 127.3, 127.3, 126.7, 125.1, 119.6, 115.4, 110.1, 101.6, 53.0,

51.7. HRMS (ESI) *m/z* ([M+H]⁺ calcd for C₁₈H₁₅NO₄S 342.0722, found 342.0796.

5-iodoindolizine-1-carbonitrile and 2-iodoindolizine-1-carbonitrile 15a and regioisomer: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and I₂ (228.4 mg, 0.9 mmol), silica gel (ethyl acetate/hexane: 8/2), ¹H NMR (400 MHz, CDCl₃, 25°C) δ 8.10 (dd, *J* = 7.0 Hz, 1H, 1H), 7.66 (d, *J* = 8.9 Hz, 1.07 H), 7.62 (dd, *J* = 9.0 Hz, 1.0 Hz, 0.92 H), 7.55 (d, *J* = 3.0 Hz, 0.92 H), 7.29 (d, *J* = 7.0 Hz, 1.20 H), 7.21 (s, 0.93 H), 7.10–7.14 (m, 1.96 H), 6.91 (t, *J* = 6.8 Hz, 1.17 H), 6.80 (dd, *J* = 9.0 Hz, 7.0 Hz, 1.02 H). ¹³C NMR (100 MHz, CDCl₃) δ 140.4, 138.3, 127.2, 125.3, 125.2, 122.7, 122.4, 119.1, 117.7, 117.6, 116.5, 115.7, 113.8, 88.1, 84.7. Note: proportional integration of H. 96:4 (product 15a).

5-iodoindolizine-1-carbonitrile 15a: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and I₂ (228.4 mg, 0.9 mmol), silica gel (ethyl acetate/hexane: 8/2), yield: 104 mg (78%), green solid, mp: 131°C, IR (KBr): 2976, 2917, 2211, 1490, 1293, 1179, 765, 725, 684. ¹H NMR (400 MHz, CDCl₃, 25°C) δ 7.66 (d, *J* = 8.8 Hz, 1H), 7.54 (d, *J* = 3.0 Hz, 1H), 7.29 (d, *J* = 7.0 Hz, 1H), 7.11 (d, *J* = 3.0 Hz, 1H), 6.80 (dd, *J* = 8.8 Hz, 7.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 138.3, 125.3, 122.4, 119.1, 117.6, 116.5, 113.8, 88.1, 84.6. HRMS (ESI) *m/z* 268.9570 ([M+H]⁺ calcd for C₉H₅IN₂: 268.9573.

2-(1-hydroxy-2-methylpropyl)indolizine-1-carbonitrile 16a: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and isobutyraldehyde (0.09 mL, 0.9 mmol), silica gel (ethyl acetate/hexane: 3/7), yield: 88 mg (82%), brown oil. IR (KBr): 3429, 2962, 2873, 2211, 1513, 1461, 1368, 1311, 1162, 1011, 829, 745. ¹H NMR (400 MHz, DMSO-*d*₆, 25°C) δ 8.34 (d, *J* = 7.0 Hz, 1H), 7.55 (d, *J* = 9.0 Hz, 1H), 7.05 (ddd, *J* = 9.0 Hz, 7.0 Hz, 0.8 Hz, 1H), 6.87 (s, 1H), 6.76 (td, *J* = 7.0 Hz, 1.1 Hz, 1H), 4.59 (d, *J* = 8.0 Hz, 1H), 2.29 (sext, *J* = 6.7 Hz, 1H), 1.15 (d, *J* = 6.6 Hz, 3H), 6.86 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 138.6, 126.8, 125.4, 122.2, 117.6, 117.1, 115.0, 112.5, 80.1, 72.5, 31.9, 19.7, 18.6. HRMS (ESI) *m/z* ([M+H]⁺ calcd for C₁₃H₁₄N₂O + Na⁺ 237.0998, found 237.100.

3-(trimethylsilyl)indolizine-2-carbonitrile 17a: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and TMSCl (0.12 mL, 0.9 mmol), silica gel (ethyl acetate/hexane: 8/2), yield: 72 mg (67%), grey oil. IR (KBr): 3128, 3055, 2960, 2226, 1519, 1422, 1349, 1310, 1249, 1120, 772, 627. ¹H NMR (400 MHz, CDCl₃, 25°C) δ 8.03 (dd, *J* = 7.1 Hz, 1.0 Hz, 1H), 7.41 (dt, *J* = 9.0 Hz, 1.1 Hz, 1H), 6.83 (ddd, *J* = 9.0 Hz, 6.5 Hz, 1.0 Hz, 1H), 6.77 (s, 1H), 6.63 (m, 1H), 0.52 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 136.1, 128.9, 126.2, 120.0, 119.6, 118.0, 112.8, 105.8, 105.4, -0.77 (3C). HRMS (ESI) *m/z* ([M+H]⁺ calcd for C₁₂H₁₄N₂Si 215.0999, found 215.1005.

3-chloroindolizine-2-carbonitrile 17b: From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and hexachloroethane (214 mg, 0.9 mmol), silica gel (ethyl acetate/hexane: 8/2), yield: 45 mg (51%), grey oil. ¹H NMR (400 MHz, CDCl₃, 25°C) δ 7.91 (d, *J* = 7.0 Hz, 1H), 7.38 (d, *J* = 9.0 Hz, 1H), 6.77–6.86 (m, 2H), 6.73 (s, 1H). ¹³C NMR (CDCl₃, 100 MHz) δ 131.7, 121.6, 119.8, 119.3, 114.4, 113.7, 112.5, 102.0, 96.6. HRMS (ESI) *m/z* ([M+H]⁺ calcd for C₉H₅ClN₂ 177.0141, found 177.0160.

General Procedure 4: Selective magnesiation of indolizines followed by Negishi Cross Coupling Reaction: After magnesiation step (according to GP3), the temperature was warmed at 0°C, and ZnCl₂ (1.0 M in THF, 2.0 equiv) was added dropwise to the reaction mixture. The temperature was kept for 30 min. Then, a THF solution of [Pd(PPh₃)₄] (10 mol%) and 1 mL of a THF solution of appropriate electrophile (1.8 equiv) were added, and the reaction mixture was kept under stirring for 12h at 60°C. The reaction was quenched with saturated aqueous NH₄Cl; the products were extracted with ethyl acetate (3 × 15 mL), and the organic layer was dried over MgSO₄. The solvent was removed under reduction pressure. The residue was

COMMUNICATION

purified by flash column chromatography (silica gel, ethyl acetate/hexanes). Results are presented in Table 1.

Dimethyl 3-phenylindolizine-1,2-dicarboxylate 14b: From dimethyl indolizine-1,2-dicarboxylate (116.5 mg, 0.5 mmol) and iodobenzene (0.10 mL, 0.9 mmol) silica gel (ethyl acetate/hexane 2/8), yield 99 mg (64%), green oil. ^1H NMR (400 MHz, CDCl_3 , 25°C) δ 8.23 (dt, $J = 9.1$, 1.3 Hz, 1H), 8.05 (dt, $J = 7.1$, 1.1 Hz, 1H), 7.51 (dd, $J = 4.2$, 0.8 Hz, 4H), 7.49 – 7.45 (m, 1H), 7.13 (ddd, $J = 9.2$, 6.6, 1.1 Hz, 1H), 6.72 (td, $J = 6.9$, 1.4 Hz, 1H), 3.91 (s, 3H), 3.81 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.0, 164.4, 135.4, 130.1, 129.2, 129.0, 125.2, 123.7, 122.2, 120.5, 113.6, 102.1, 52.6, 51.4. HRMS (ESI) m/z ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{18}\text{H}_{15}\text{NO}_4$ 310.1001, found 310.1069.

Dimethyl 3-(4-(trifluoromethyl)phenyl)indolizine-1,2-dicarboxylate 14c: From dimethyl indolizine-1,2-dicarboxylate (116.5 mg, 0.5 mmol) and 1-bromo-4-(trifluoromethyl)benzene (0.12 mL, 0.9 mmol), silica gel (ethyl acetate/hexane 2/8), yields 143 mg (76%). ^1H NMR (400 MHz, CDCl_3 , 25°C) δ 8.26 (dt, $J = 9.1$, 1.2 Hz, 1H, H-8), 8.03 (dt, $J = 7.2$, 1.1 Hz, 1H, H-5), 7.81 – 7.74 (m, 2H), 7.70 – 7.63 (m, 2H), 7.21 – 7.13 (m, 1H, H-7), 6.78 (td, $J = 6.9$, 1.3 Hz, 1H, H-6), 3.91 (s, 3H), 3.82 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.64, 164.19, 135.72, 130.42, 126.3 (q, $J_{\text{FC}} = 3.1$, 2.7 Hz, 2C, C-3', C5'), 124.1 (q, $J_{\text{FC}} = 272$ Hz, CF₃), 120.8, 114.1, 102.7, 52.8, 51.6. HRMS (ESI) m/z ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{19}\text{H}_{14}\text{F}_3\text{NO}_4$ 378.0875, found 378.0941.

General Procedure 5: Selective Lithiation of indolizines using LDA:

In a dry round-bottom flask under magnetic stirring, LDA was prepared by addition of *n*-butyllithium (2.35 M in hexanes, 0.70 mmol, 0.30 mL, 1.4 equiv) to a solution of diisopropylamine (0.77 mmol, 0.10 mL, 1.54 equiv) in THF (1 mL) at –70°C. After 15 min, the reaction mixture was warmed to 0°C and stirred for 20 min at the same temperature. After, indolizine-carbonitrile (71 mg, 0.5 mmol) in THF (2 mL) was added dropwise to the reaction mixture. After stirring for 30 min at 0°C, a solution of an appropriate electrophile (1.8 equiv) in THF (1.0 mL) was added, and the reaction mixture was kept under stirring for 2h (for iodine) and 12h (other electrophiles). The reaction was quenched with saturated aqueous NH_4Cl , the products were extracted with ethyl acetate (3 × 15 mL), and the organic layers were dried over MgSO_4 . The solvent was removed under reduced pressure. The residue was purified by flash column chromatography (silica gel, hexanes/ethyl acetate). Results are presented in Scheme 3.

5-(1-hydroxy-2-methylpropyl)indolizine-1-carbonitrile 15b : From indolizine-1-carbonitrile (71 mg, 0.5 mmol) and isobutyraldehyde (0.09 mL, 0.9 mmol), silica gel (ethyl acetate/hexane: 3/7), yield: 79 mg (74%), brown oil. IR (KBr): 3426, 3104, 2962, 2928, 2867, 2203, 1520, 1464, 1389, 1259, 1159, 1010, 787, 695. ^1H NMR (400 MHz, CDCl_3 , 25°C) δ 7.44–7.46 (m, 2H), 7.05 (dd, $J = 8.9$ Hz, $J = 6.8$ Hz, 1H), 6.96 (d, $J = 3.0$ Hz, 1H), 6.81 (d, $J = 6.7$ Hz, 1H), 4.70 (d, $J = 6.4$ Hz, 1H), 2.29 (sext, $J = 6.6$ Hz, 1H), 1.03 (d, $J = 6.6$ Hz, 3H), 0.94 (d, $J = 6.6$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 139.5, 138.9, 122.1, 117.2, 116.4, 116.3, 112.4, 111.1, 81.1, 77.3, 77.0, 76.6, 75.9, 30.1, 19.7, 17.3. HRMS (ESI) m/z ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O} + \text{Na}^+$ 237.0998 found 237.1003.

General Procedure 6: Selective Magnesiation of indolizines using $\text{TMP}_2\text{MgCl} \cdot 2\text{LiCl}$:

In a dry round-bottom flask under magnetic stirring, $\text{TMP}_2\text{MgCl} \cdot 2\text{LiCl}$ was prepared by addition of *n*-butyllithium (2.48 M in hexanes, 1.0 mmol, 0.40 mL) to a solution of $\text{TMPMgCl} \cdot \text{LiCl}$ (1.05 mmol, 0.18 mL) in THF (2 mL) at –70 °C. After 5 min, the reaction mixture was warmed to 0°C and stirred for 30 min at the same temperature. A solution of $\text{TMPMgCl} \cdot \text{LiCl}$ (1.0 M in THF, 1.0 mmol, 1 mL) was added dropwise to the reaction mixture. The temperature was held at 0°C for 15 min and warmed up to room temperature. After 30 min, a solution of indolizine-2-carbonitrile (71 mg, 0.5 mmol) in THF (2 mL) was added. After stirring for 1h at room temperature, a solution of an appropriate electrophile (1.8 equiv) in

THF (1.0 mL) was added, and the reaction mixture was kept under stirring for 2h (for iodine) and 12h (other electrophiles). The reaction was quenched with saturated aqueous NH_4Cl , the products were extracted with ethyl acetate (3 × 15 mL), and the organic layers were dried over MgSO_4 . The solvent was removed under reduced pressure. The residue was purified by flash column chromatography (silica gel, ethyl acetate/hexanes). Results are presented in Scheme 3.

5-iodoindolizine-2-carbonitrile 18a: From dimethyl indolizine-2-carbonitrile (71 mg, 0.5 mmol) and I_2 (228.4 mg, 0.9 mmol), silica gel (ethyl acetate/hexane: 8/2), yield: 104 mg (78%), pale yellow solid, mp: 140–142°C. IR (KBr): 3133, 3119, 2962, 2229, 1493, 1288, 1207, 1125, 788, 721. ^1H NMR (400 MHz, CDCl_3 , 25°C) δ 7.95 (m, 1H), 7.42 (d, $J = 9.0$ Hz, 1H), 7.19 (dd, $J = 6.9$ Hz, 1.0 Hz, 1H), 6.93 (d, $J = 1.6$ Hz, 1H), 6.56 (dd, $J = 9.0$ Hz, 6.9 Hz, 1H). ^{13}C NMR (400 MHz, CDCl_3) δ 133.2, 125.5, 122.9, 119.9, 119.6, 115.9, 105.0, 97.2, 85.8. HRMS (ESI) m/z ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_9\text{H}_5\text{IN}_2$ 268.9570, found 268.9574.

Acknowledgments

Authors are grateful to FAPESP (Process 2015/03007-1, 2014/2360-1, 2011/20742-6 and 2018/14150-8), FAPESP-Durham University (Sprint project 2017/50381-1), CNPq (442384/2014-9) and Capes for financial support. SDS thank Astra Zeneca and the EPSRC for support a studentship. PGS acknowledges receipt of a Royal Society International Collaboration Award IC160044.

Keywords: C-H borylation • C-H metalation • Indolizines • Suzuki-Miyaura cross coupling • Negishi cross coupling

- [1] K. M. Dawood, H. Abdel-Gawad, M. Ellithy, H. A. Mohamed, B. Hegazi, *Arch. Pharm. Chem. Life Sci.* **2006**, 339, 133–140.
- [2] W. M. Bloch, S. M. Derwent-Smith, F. Issa, J. C. Morris, L. M. Rendina, C. J. Sumby, *Tetrahedron* **2011**, 67, 9368–9375.
- [3] A. Hazra, S. Mondal, A. Maity, S. Naskar, P. Saha, R. Paira, K. B. Sahu, P. Paira, S. Ghosh, C. Sinha, A. Samanta, S. Banerjee, N. B. Mondal, *Eur. J. Med. Chem.* **2011**, 46, 2132–2140.
- [4] T. Weide, L. Arve, H. Prinz, H. Waldmann, H. Kessler, *Bioorganic Med. Chem. Lett.* **2006**, 16, 59–63.
- [5] L. Gundersen, A. H. Negussie, F. Rise, O. B. Østby, *Arch. Pharm. Pharm. Med. Chem.* **2003**, 336, 191–195.
- [6] P. Sonnet, P. Dallemagne, J. Guillon, C. Enguehard, S. Stiebing, J. Tanguy, R. Bureau, S. Rault, P. Auvray, S. Moslemi, P. Sourdaire, G. Seralini, *Bioorg. Med. Chem.* **2000**, 8, 945–955.
- [7] S. Chen, Z. Xia, M. Nagai, R. Lu, E. Kostik, T. Przewloka, M. Song, D. Chimmanamada, D. James, S. Zhang, J. Jiang, M. Ono, K. Koya, L. Sun, *Med. Chem. Comm.* **2011**, 2, 176–180.
- [8] S. C. Smith, E. D. Clarke, S. M. Ridley, D. Bartlett, D. T. Greenhow, H. Glithro, A. Y. Klong, G. Mitchell, G. W. Mullier, *Pest Manag. Sci.* **2005**, 61, 16–24.
- [9] A. I. Nasir, L. L. Gundersen, F. Rise, Ø. Antonsen, T. Kristensen, B. Langhelle, A. Bast, I. Custers, G. R. M. M. Haenen, H. Wikström, *Bioorg. Med. Chem. Lett.* **1998**, 8, 1829–1832.
- [10] S. Teklu, L. L. Gundersen, T. Larsen, K. E. Malterud, F. Rise, *Bioorg. Med. Chem.* **2005**, 13, 3127–3139.


COMMUNICATION

- [11] W. Chai, J. G. Breitenbucher, A. Kwok, X. Li, V. Wong, N. I. Carruthers, T. W. Lovenberg, C. Mazur, S. J. Wilson, F. U. Axe, T. K. Jones, *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1767–1770.
- [12] S. Medda, P. Jaisankar, R. K. Manna, B. Pal, V. S. Giri, M. K. Basu, *J. Drug Target.* **2003**, *11*, 123–128.
- [13] E. Kim, S. Lee, S. B. Park, *Chem. Commun.*, **2011**, *47*, 7734–7736.
- [14] M. S. Jeong, E. Kim, H. J. Kang, E. J. Choi, A. R. Cho, S. J. Chung, S. B. Park, *Chem. Commun.* **2012**, *48*, 6553–6555.
- [15] E. J. Choi, E. Kim, Y. Lee, A. Jo, S. B. Park, *Angew. Chemie. Int. Ed.* **2014**, *53*, 1346–1350.
- [16] G. G. Surpateanu, M. Becuwe, N. C. Lungu, P. I. Dron, S. Fourmentin, D. Landy, G. Surpateanu, *J. Photochem. Photobiol. A Chem.* **2007**, *185*, 312–320.
- [17] Y. Lee, S. Na, S. Lee, N. L. Jeon, S. B. Park, *Mol. BioSyst.* **2013**, *9*, 952–956.
- [18] B. Liu, Z. Wang, N. Wu, M. Li, J. You, J. Lan, *Chem. Eur. J.* **2012**, *18*, 1599–1603.
- [19] Y. Zhang, J. Garcia-Amorós, B. Capitana, F. M. Raymo, *J. Mater. Chem.* **2016**, *4*, 2744–2747.
- [20] A. J. Huckaba, F. Giordano, L. E. McNamara, K. M. Dreux, N. I. Hammer, G. S. Tschumper, S. M. Zakeeruddin, M. Grätzel, M. K. Nazeeruddin, J. H. Delcamp, *Adv. Energy Mater.* **2015**, *5*, 1401629.
- [21] E. Kim, Y. Lee, S. Lee, S. B. Park, *Acc. Chem. Res.* **2015**, *48*, 538–547.
- [22] G. S. Singh, E. E. Mmatli, *Eur. J. Med. Chem.* **2011**, *46*, 5237–5257.
- [23] V. R. Vemula, S. Vurukonda, C. K. Bairi, *Int. J. Pharm. Sci. Rev. Res.* **2011**, *11*, 159–163.
- [24] V. Sharma, V. Kumar, *Med. Chem. Res.* **2014**, *23*, 3593–3606.
- [25] C. R. de Souza, A. C. Gonçalves, M. F. Z. J. Amaral, A. A. Dos Santos, G. C. Clososki, *Targets Heterocycl. Syst.* **2016**, *20*, 365–392.
- [26] M. Renard, J. Gubin, *Tetrahedron Lett.* **1992**, *33*, 4433–4434.
- [27] a) A. G. Kuznetsov, A. A. Bush, V. B. Rybakov, E. V. Babaev, *Molecules* **2005**, *10*, 1074–1083; b) A. G. Kuznetsov, A. A. Bush, E. V. Babaev, *Tetrahedron* **2008**, *64*, 749–756; c) I. A. Shadrin, S. A. Rzhetskii, V. B. Rybakov, E. V. Babaev, *Synth.* **2015**, *47*, 2961–2964; d) S. A. Rzhetskii, V. B. Rybakov, V. N. Khrustalev, E. V. Babaev, *Molecules* **2017**, *22*, 661–671; e) M. F. Z. J. Amaral, L. A. Deliberto, C. R. De Souza, R. M. Z. G. Naal, Z. Naal, G. C. Clososki, *Tetrahedron* **2014**, *70*, 3249–3258;
- [28] a) L. A. Bozzini, J. H. Batista, M. B. de Mello, R. Vessecchi, G. C. Clososki, *Tetrahedron Lett.*, **2017**, *58*, 4186–4190; b) V. E. Murie, R. H. V. Nishimura, L. A. Rolim, R. Vessecchi, N. P. Lopes, G. C. Clososki, *J. Org. Chem.*, **2017**, *83*, 871–880; c) J. H. Batista, F. M. Santos, L. A. Bozzini, R. Vessecchi, A. R. M. Oliveira, G. C. Clososki, *Eur. J. Org. Chem.*, **2015**, 967; d) F. M. Santos, J. H. Batista, R. Vessecchi, G. C. Clososki, *Synlett*, **2015**, 26, 2795–2800; e) M. F. Z. J. Amaral, A. A. Baumgartner, R. Vessecchi, G. C. Clososki, *Org. Lett.* **2015**, *17*, 238–241.
- [29] a) A. Krasovskiy, V. Krasovskaya, P. Knochel *Angew. Chem. Int. Ed.* **2006**, *45*, 2958–2961; b) W. Lin, W. O. Baron, P. Knochel, *Org. Lett.* **2006**, *8*, 5673–5676; c) M. A. Ganiek, M. R. Becker, M. Ketels, P. Knochel, *Org. Lett.* **2016**, *18*, 828–831; d) G. C. Clososki, C. J. Rohbogner, P. Knochel, *Angew. Chem. Int. Ed.* **2007**, *46*, 7681–7684; e) Z. B. Dong, G. C. Clososki, S. H. Wunderlich, A. Unsinn, J. S. Li, P. Knochel, *Chem. Eur. J.* **2009**, *15*, 457–468; f) Z. B. Dong, W. H. Zhu, Z. G. Zhang, M. Z. Li, *J. Organomet. Chem.* **2010**, *695*, 775–780; g) Rohbogner, C. J.; Wunderlich, S. H.; Clososki, G. C.; Knochel, P. *Eur. J. Org. Chem.* **2009**, 1781–1795; h) R. H. V. Nishimura, A. de L. L. Vaz, L. A. Bozzini, V. E. Murie, G. C. Clososki, *Tetrahedron*, **2019**, *75*, 464–474.
- [30] I. A. I. Mkhaliid, J. H. Barnard, T. B. Marder, J. M. Murphy, J. F. Hartwig, *Chem. Rev.* **2010**, *110*, 2, 890–931.
- [31] a) L. Zhang, F. Liang, L. Sun, Y. Hu, H. Hu, *Synthesis (Stuttg.)* **2000**, 1733–1737; b) M. D. S. Cunha, R. G. de Oliveira, M. L. A. A. Vasconcellos, *J. Braz. Chem. Soc.*, **2013**, *24*, 432–438; c) R. Uson, L. A. Oro, J. A. Cabeza, *Inorg. Synth.*, **1985**, *23*, 126–130.
- [32] T. Ishiyama, Y. Nobuta, J. F. Hartwig, N. Miyaura, *Chem. Commun.* **2003**, 2924–2925.
- [33] J. M. Murphy, M. Hapke, J. F. Hartwig, T. Ishiyama, T. M. Boller, N. Miyaura, *J. Am. Chem. Soc.* **2005**, *127*, 14263–14278.
- [34] a) S. A. Sadler, H. Tajuddin, I. A. I. Mkhaliid, A. S. Batsanov, D. Albesa-Jove, M. S. Cheung, A. C. Maxwell, L. Shukla, B. Roberts, D. C. Blakemore, Z. Lin, T. B. Marder, P. G. Steel, *Org. Biomol. Chem.*, **2014**, *12*, 7318–7327; b) S. A. Sadler, A. C. Hones, B. Roberts, D. C. Blakemore, T. B. Marder, P. G. Steel *J. Org. Chem.*, **2015**, *80*, 5308–5314; c) H. Tajuddin, P. Harrison, B. Bitterlich, J. C. Collings, N. Sim, A. S. Batsanov, M. S. Cheung, S. Kawamori, A. C. Maxwell, L. Shukla, J. Morris, Z. Lin, T. B. Marder, P. G. Steel, *Chem. Sci.* **2012**, *3*, 3505–3515.
- [35] P. Harrison, J. Morris, P. G. Steel, T. B. Marder, *Synlett* **2009**, 147–150.
- [36] a) D. Haas, J. M. Hammann, R. Greiner, P. Knochel, *ACS Catal.* **2016**, *6*, 1540–1552; b) S. Sase, M. Jaric, A. Metzger, V. Malakhov, P. Knochel, *J. Org. Chem.* **2008**, *73*, 7380–7382; c) C. C. C. Johansson Seechurn, M. O. Kitching, T. J. Colacot, V. Snieckus, *Angew. Chem. Int. Ed.* **2012**, *51*, 5062–5085; d) J. T. Binder, C. J. Cordier, G. C. Fu, *J. Am. Chem. Soc.* **2012**, *134*, 17003–17006; e) M. F. Z. J. Amaral, D. R. Callejon, T. B. Riul, M. D. Baruffi, F. T. Toledo, N. P. Lopes, G. C. Clososki, *J. Braz. Chem. Soc.* **2014**, *25*, 1907–1913.
- [37] Calculations were performed in a Gaussian 03 suite program: Frisch, G. E. S. M. J.; Trucks, G. W.; Schlegel, H. B.; Robb, T. V. M. A.; Cheeseman, J. R.; Montgomery, J. A.; Kudin, Jr., J. T. K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, N. R. V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, K. T. G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, O. K. R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Nakai, J. B. C. H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, R. E. S. V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, J. W. O. O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, P. Y.; Ayala, J. J. D. P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, M. C. S. V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, K. R. O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, S. C. J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Cioslowski, P. P. J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; The Journal of Organic Chemistry Article DOI: 10.1021/acs.joc.7b02855 *J. Org. Chem.* **2018**, *83*, 871–880 879 Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. *Gaussian 03*; Gaussian, Inc.: Wallingford, CT, 2004.
- [38] N. M. Brikci-Nigassa, G. Bentabed-Ababsa, W. Erb, F. Mongin *Synthesis* **2018**, *50*, 3615–3633.
- [39] a) F. Mongin, A. Tognini, F. Cottet, M. Schlosser *Tetrahedron Lett.* **1998**, *39*, 1749–1752; b) M. Balkenhohl, R. Greiner, I. S. Makarov, B. Heinz, K. Karaghiosoff, H. Zipse, P. Knochel *Chem. Eur. J.* **2017**, *23*, 13046–13050; c) Y. Hayashi, K. Okano, A. Mori, *Org. Lett.* **2018**, *20*, 958–961.

COMMUNICATION

Entry for the Table of Contents (Please choose one layout)

COMMUNICATION



Indolizines represent a privileged class of heterocycles with several applications in Organic Synthesis and Medicinal Chemistry. In this work, the C-H borylation of aryl indolizines is described for the first time and contrasted to directed metalation. These complementary approaches allowed us to obtain a variety of substituted indolizines functionalized in both pyridinic and pyrrole ring.

Functionalized indolizines

Camila R. de S. Bertallo, Thais R. Arroio,
Mônica F. Z. J. Toledo, Scott D. Saddler,
Ricardo Vessechi, Patrick G. Steel,*
Giuliano C. Clososki^[a]

Page No. – Page No.

**C-H Activation / metalation
approaches for the synthesis of
indolizine derivatives**